Case Study Shows Potential Protective Effect of TKI Therapy for Chronic Myeloid Leukemia
A case study with a literature review demonstrates potential antiviral effect of TKI therapy in patients with cancer and COVID-19.
Acute Myeloid Leukemia
Whole-Genome Sequencing Is Accurate for Myeloid Cancers
Prospective sequencing of samples provided new genetic information for 24.8 percent of patients, which changed risk category for 16.2 percent.
Acute Kidney Injury Seen With Induction Chemotherapy for Acute Myeloid Leukemia
Researchers sought to determine the incidence and risk factors for acute kidney in patients with AML who are undergoing induction chemotherapy.
Cytogenetics Predict Outcomes to Venetoclax Combination Therapy in Relapsed/Refractory Acute Myeloid Leukemia
Researchers sought to determine whether molecular characteristics could help predict responses to treatments with venetoclax in patients with relapsed or refractory AML.
Azacitidine Plus Venetoclax Is Not Cost-Effective for Some Patients With AML
Cost-effectiveness model was developed to compare costs and other factors of azacitidine/venetoclax combination with azacitidine alone in patients with AML.
Next-Generation Approaches to Karyotyping in Acute Myeloid Leukemia
Researchers revisited the techniques traditionally used to assess CNAs and translocations in routine AML diagnostics to challenge the recommended CCA.
Clinical Trial: Investigators Testing E-selectin Antagonist/Chemotherapy Combination in R/R AML
Uproleselan will be evaluated in combination with chemotherapy in a phase 3 trial of patients with relapsed or refractory acute myeloid leukemia (AML).
Leukemia: Fact Sheet for Patients
Almost everyone has heard of leukemia, but most people do not have a good understanding of this complex disease. How can healthcare providers explain the basics of leukemia to their patients?
Flotetuzumab Therapy for Relapsed/Refractory Acute Myeloid Leukemia
Researchers sought to find out if flotetuzumab shows activity with an acceptable safety profile in patients with acute myeloid leukemia and primary induction failure or early relapse.
Thymoglobulin as GVHD Prophylaxis in AML Conditioning Regimens
Study authors retrospectively evaluated effect of thymoglobulin addition in RIC and MAC regimens on the cumulative incidence and severity of acute and chronic GVHD, overall survival, and relapse rate in adult AML patients who underwent URD PBSCT.
-
Loading...
-
Loading...
